Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Laser Photonics Announces Strategic Milestone on Advanced Laser Shield Anti Drone System (click to learn more) This emerging Bitcoin infrastructure company is building a vertically integrated model (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Marijuana Inc (ID) MAJI

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Exousia Pro, Inc., a clinical stage biotechnology company, develops ways to exploit the therapeutic potential of exosomes for the field of oncology in the United States. The company was formerly known as Marijuana, Inc. and changed its name to Exousia Pro, Inc. in April 2025. Exousia Pro, Inc. was incorporated in 2010 and is based in Saint Petersburg, Florida.

Recent & Breaking News ()

NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test

GlobeNewswire 8 days ago

Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value

GlobeNewswire March 16, 2026

Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions

GlobeNewswire March 5, 2026

Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition

GlobeNewswire February 10, 2026

Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization

ACCESS Newswire December 11, 2025

Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement

ACCESS Newswire December 5, 2025

Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms

ACCESS Newswire December 2, 2025

Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value

ACCESS Newswire November 17, 2025

Exousia Pro Announces Breakthrough In Exosome-Based Delivery

ACCESS Newswire November 4, 2025

Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA

ACCESS Newswire October 28, 2025

Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes

ACCESS Newswire September 29, 2025

Exousia Pro Reports Positive Outcome in Legal Proceeding

ACCESS Newswire September 26, 2025

Exousia Pro Files Provisional Patent for Novel Extracellular Vesicle Loading Method, Tapping into Multi-Billion Dollar Markets

ACCESS Newswire September 10, 2025

Exousia Pro Announces Strategic Acquisition to Launch a New Telehealth Division

ACCESS Newswire September 8, 2025

Exousia Pro Creates New Subdivisions

ACCESS Newswire September 3, 2025

Exousia Pro Files Reg A.

ACCESS Newswire June 25, 2025

Exousia Pro Expands its Scientific Advisory Board

ACCESS Newswire June 18, 2025

Exousia Pro Will Launch a Web Series with Our New Consultant

ACCESS Newswire April 30, 2025

Exousia Pro Finishes Preclinical Trial for Glioblastoma Ahead of Schedule - Bolstering Orphan Drug Application

ACCESS Newswire April 29, 2025

Exousia Pro CSO Revealed Significant Findings About the Glioblastoma Study in a Spaces Interview

ACCESS Newswire April 21, 2025

Podcasts